Drug Trial Radar · NCT07699939
Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
136
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Nov 30, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- National Cancer Center, JapanGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Jul 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the clinical efficacy of perioperative treatment with S-1 + oxaliplatin (SOX)+ HLX10 compared with SOX as the control in patients with cT3-4N1-3M0 PD-L1-positive (CPS ≥ 5) locally advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, in a placebo-controlled, double-blind, randomized phase II investigator-initiated clinical study.
Conditions
- Gastric Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
serplulimabDrug
Patients receive perioperative treatment with S-1 plus oxaliplatin (SOX) in combination with Serplulimab.
PlaceboDrug
Patients receive perioperative treatment with S-1 plus oxaliplatin (SOX) in combination with placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological complete response (pCR) rate by central pathology reviewTime frame: Approximately 4-5 months after randomization (after surgery)
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
Chiba Cancer Center
Chiba, Chiba, Japan · Recruiting
Kyushu Cancer Center
Fukuoka, Fukuoka, Japan · Recruiting
Gifu University Hospital
Gifu, Gifu, Japan · Recruiting
Gunma University Hospital
Maebashi, Gunma, Japan · Recruiting
Hiroshima University Hospital
Hiroshima, Hiroshima, Japan · Recruiting
St. Marianna University Hospital
Kawasaki, Kanagawa, Japan · Recruiting
Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
Yokohama, Kanagawa, Japan · Recruiting
Saitama Prefectural Cancer Center
Ina, Kitaadachi-gun, Japan · Recruiting
Osaka International Cancer Institute
Osaka, Osaka, Japan · Recruiting
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, Osaka, Japan · Recruiting
Saitama Medical University International Medical Center
Hidaka, Saitama, Japan · Recruiting
Shizuoka Cancer Center
Nagaizumi-chō, Sunto-gun, Japan · Recruiting
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan · Recruiting
Cancer Institute Hospital of JFCR
Koto-Ku, Tokyo, Japan · Recruiting
Keio University Hospital
Shinjuku-Ku, Tokyo, Japan · Recruiting
Asan Medical Center
Songpa-dong, South Korea · Not yet recruiting
National Cancer Center Korea
Goyang-si, Gyeonggi-do, South Korea · Not yet recruiting
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea · Not yet recruiting
Seoul St. Mary's Hospital
Seocho, Seoul, South Korea · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.